Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction

References

• BraunsteinJBChengACohnGAggarwalMNassCMBlumenthalRSLipid disorders: justification of methods and goals of treatmentChest2001120397998811555537
   PubMed Web of Science ®Google Scholar
• SendersASandoKWahbehHHillerAPShintoLManaging psychological stress in the multiple sclerosis medical visit: Patient perspectives and unmet needsJ Health Psychol Epub20141219
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106253143342112485966
   PubMed Web of Science ®Google Scholar
• InvestigatorsA-HBodenWEProbstfieldJLNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMed Web of Science ®Google Scholar
• GroupASGinsbergHNElamMBEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563157420228404
   PubMed Web of Science ®Google Scholar
• TaylorFHuffmanMDMacedoAFStatins for the primary prevention of cardiovascular diseaseCochrane Database Syst Rev20131CD00481623440795
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaboratorsMihaylovaBEmbersonJThe effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trialsLancet2012380984158159022607822
   PubMed Web of Science ®Google Scholar
• JoyTRHegeleRANarrative review: statin-related myopathyAnn Int Med20091501285886819528564
   PubMed Web of Science ®Google Scholar
• FellstromBCJardineAGSchmiederRERosuvastatin and cardiovascular events in patients undergoing hemodialysisN Engl J Med2009360141395140719332456
   PubMed Web of Science ®Google Scholar
• KjekshusJApetreiEBarriosVRosuvastatin in older patients with systolic heart failureN Engl J Med2007357222248226117984166
   PubMed Web of Science ®Google Scholar
• GissiHFITavazziLMaggioniAPEffect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialLancet200837296451231123918757089
   PubMed Web of Science ®Google Scholar
• WannerCKraneVMarzWAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisN Engl J Med2005353323824816034009
   PubMed Web of Science ®Google Scholar
• CannonCPBlazingMAGiuglianoRPEzetimibe added to statin therapy after acute coronary syndromesN Engl J Med2015372252387239726039521
   PubMed Web of Science ®Google Scholar
• BohulaEAGiuglianoRPCannonCPAchievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-ITCirculation2015132131224123326330412
   PubMed Web of Science ®Google Scholar
• CohenJCBoerwinkleEMosleyTHJrHobbsHHSequence variations in PCSK9, low LDL, and protection against coronary heart diseaseN Engl J Med2006354121264127216554528
   PubMed Web of Science ®Google Scholar
• HortonJDCohenJCHobbsHHMolecular biology of PCSK9: its role in LDL metabolismTrends Biochem Sci2007322717717215125
   PubMed Web of Science ®Google Scholar
• SteinEAMellisSYancopoulosGDEffect of a monoclonal antibody to PCSK9 on LDL cholesterolN Engl J Med2012366121108111822435370
   PubMed Web of Science ®Google Scholar
• AbifadelMVarretMRabesJPMutations in PCSK9 cause autosomal dominant hypercholesterolemiaNat Genet200334215415612730697
   PubMed Web of Science ®Google Scholar
• CiceroAFCollettiABorghiCProfile of evolocumab and its potential in the treatment of hyperlipidemiaDrug Des Devel Ther2015930733082
   PubMed Web of Science ®Google Scholar
• SteinEWassermanSDiasCScottRRaalFAMG145Drug Future201338451459
   Web of Science ®Google Scholar
• Repatha™ [package insert]Thousand Oaks, CAAmgen Inc.2015
   Google Scholar
• GazzerroPProtoMCGangemiGPharmacological actions of statins: a critical appraisal in the management of cancerPharmacol Rev201264110214622106090
   PubMed Web of Science ®Google Scholar
• KorenMJLundqvistPBologneseMAnti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumabJ Am Coll Cardiol201463232531254024691094
   PubMed Web of Science ®Google Scholar
• RobinsonJGNedergaardBSRogersWJEffect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trialJAMA2014311181870188224825642
   PubMed Web of Science ®Google Scholar
• BlomDJHalaTBologneseMA 52-week placebo-controlled trial of evolocumab in hyperlipidemiaN Engl J Med2014370191809181924678979
   PubMed Web of Science ®Google Scholar
• SabatineMSGiuglianoRPWiviottSDEfficacy and safety of evolocumab in reducing lipids and cardiovascular eventsN Engl J Med2015372161500150925773607
   PubMed Web of Science ®Google Scholar
• StroesEColquhounDSullivanDAnti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumabJ Am Coll Cardiol201463232541254824694531
   PubMed Web of Science ®Google Scholar
• RaalFJSteinEADufourRPCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialLancet2014385996533134025282519
   PubMed Web of Science ®Google Scholar
• RaalFJHonarpourNBlomDJInhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialLancet2015385996534135025282520
   PubMed Web of Science ®Google Scholar
• AmgenFurther cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER)2015 Available from: https://clinicaltrials.gov/ct2/show/NCT01764633?term=FOURIER&rank=6Accessed August 25, 2015
   Google Scholar
• AmgenStudy to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen2013 Available from: https://clinicaltrials.gov/ct2/show/NCT01879319?term=20120356&rank=1Accessed August 25, 2015
   Google Scholar
• AmgenStudy to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen2013 Available from: https://clinicaltrials.gov/show/NCT01849497Accessed August 25, 2015
   Google Scholar
• WalldiusGJungnerIThe apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy–a review of the evidenceJ Int Med20062595493519
   PubMed Web of Science ®Google Scholar
• BaertFNomanMVermeireSInfluence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med2003348760160812584368
   PubMed Web of Science ®Google Scholar
• HardingFASticklerMMRazoJDuBridgeRBThe immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regionsMAbs20102325626520400861
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJGLichtensteinAH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20146325 Pt B2889293424239923
   PubMed Web of Science ®Google Scholar
• CromwellWCOtvosJDKeyesMJLDL particle number and risk of future cardiovascular disease in the Framingham offspring study – implications for LDL managementJ Clin Lipidol20071658359219657464
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors CollaborationErqouSKaptogeSLipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortalityJAMA2009302441242319622820
   PubMed Web of Science ®Google Scholar
• BoekholdtSMArsenaultBJMoraSAssociation of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysisJAMA2012307121302130922453571
   PubMed Web of Science ®Google Scholar
• (ICER) TIfCaERPCSK9 inhibitor therapies for high cholesterol: effectiveness, value, and value-based price benchmarks2015 Available from: http://cepac.icer-review.org/wp-content/uploads/2015/04/PCSK9_Draft_Report_0908151.pdfAccessed October 9, 2015
   Google Scholar
• RobsonJLipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular diseaseHeart200894101331133218701534
   PubMed Web of Science ®Google Scholar
• NavareseEPKolodziejczakMSchulzeVEffects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysisAnn Int Med20151631405125915661
   PubMed Web of Science ®Google Scholar
• LennernasHClinical pharmacokinetics of atorvastatinClin Pharmacokinet200342131141116014531725
   PubMed Web of Science ®Google Scholar